Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 19, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
COVID-19 Acute Respiratory Distress SyndromeCOVID-19
Interventions
DRUG

Plerixafor 20 MG/ML [Mozobil]

Plerixafor (Mozobil®) continuous intravenous infusion for 7 days

OTHER

Placebo

Placebo continuous intravenous infusion for 7 days

Trial Locations (14)

1142

University First Multiprofile Hospital for Active Treatment Sofia St John the Baptist, Sofia

1606

Military Medical Academy Multiprofile Hospital for Active Treatment Sofia, Sofia

University Hospital for Active Treatment and Emergency Medicine NI Pirogov EAD, Sofia

1750

MHAT Sveta Anna Sofia AD, Sofia

4002

University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv

4400

Multiprofile Hospital For Active Treatment Pazardzhik AD, Pazardzhik

6000

University Multiprofile Hospital for Active Treatment Prof Dr Stoyan Kirkovich AD, Stara Zagora

6300

Multiprofile Hospital for Active Treatment AD Haskovo, Haskovo

8800

Multiprofile Hospital for Active Treatment Dr Ivan SeliminskiSliven AD, Sliven

33000

Hôpital Saint André, Bordeaux

33604

Hôpital Haut-Lévêque, Pessac

67091

Hôpital Civil de Strasbourg, Strasbourg

85000

Centre Hospitalier Départemental de Vendée - Les Oudairies, La Roche-sur-Yon

95100

Centre Hospitalier d'Argenteuil, Argenteuil

Sponsors

Lead Sponsor

All Listed Sponsors
lead

4Living Biotech

INDUSTRY